SHR-A1201

SHR-A1201 is a HER2-targeting antibody-drug conjugate (ADC) . SHR-A1201 is composed of a humanized anti-HER2 antibody (HY-P9907), a linker SMCC (HY-42360), and a microtubulin inhibitor payload Mertansine (HY-19792) . SHR-A1201 can be used for research in HER2-positive breast cancer[1].

Product Specifications

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs) ; EGFR

Type

Reference compound

Related Pathways

Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/shr-a1201.html

Purity

97.35

Smiles

S[R][A1201]

References & Citations

[1]Xianjing Li, et al. Development and validation of pharmacokinetics assays for a novel HER2-targeting antibody-drug conjugate (SHR-A1201) : Application to its dose-escalation pharmacokinetic study. J Pharm Biomed Anal. 2024 Mar 15:240:115964.